{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T08:33:07Z","timestamp":1709109187092},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/inf.0000000000001214","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T15:43:48Z","timestamp":1463499828000},"page":"e271-e274","source":"Crossref","is-referenced-by-count":6,"title":["Rilpivirine Pharmacokinetics Without and With Darunavir\/Ritonavir Once Daily in Adolescents and Young Adults"],"prefix":"10.1097","volume":"35","author":[{"given":"Marc","family":"Foca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Yogev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wiznia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Jean-Philippe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobbie","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Britto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210202","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jac\/dkt463","article-title":"Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.","volume":"69","author":"Lambert-Niclot","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R2-12-20210202","doi-asserted-by":"crossref","first-page":"607.e1","DOI":"10.1016\/j.cmi.2015.02.011","article-title":"Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.","volume":"21","author":"Theys","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R5-12-20210202","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","article-title":"Simplification to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.","volume":"28","author":"Palella","year":"2014","journal-title":"AIDS"},{"key":"R6-12-20210202","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1097\/QAI.0000000000000401","article-title":"Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.","volume":"68","author":"Surgers","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-12-20210202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/hiv.12071","article-title":"Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load \u2264 100 000 copies\/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.","volume":"15","author":"Molina","year":"2014","journal-title":"HIV Med"},{"key":"R10-12-20210202","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/clpt.2013.62","article-title":"Clinical pharmacology quality assurance for HIV and related infectious diseases research.","volume":"93","author":"DiFrancesco","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R11-12-20210202","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/01.aids.0000242818.65215.bd","article-title":"Short-term antiviral activity of TMC278\u2013a novel NNRTI\u2013in treatment-naive HIV-1-infected subjects.","volume":"20","author":"Goebel","year":"2006","journal-title":"AIDS"},{"key":"R12-12-20210202","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/QAD.0b013e32833032ed","article-title":"Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.","volume":"24","author":"Pozniak","year":"2010","journal-title":"AIDS"},{"key":"R13-12-20210202","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"R14-12-20210202","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"R15-12-20210202","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:11:19Z","timestamp":1620954679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201609000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001214","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}